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The murine major histocompatibility complex I-J subregion has recently been 
the subject of much controversy. The Ia-4 locus within I-J encodes a suppressor 
T  lymphocyte surface marker (1), as well as a suppressor T  cell factor determinant 
(2).  Using  recombinant  strain  distribution  patterns,  independent  investigators 
mapped I-J between I-B and I-B and I-E,  in the chromosomal segment bounded 
by recombination  points  in  strains  BI0.A(5R)  and  B10.S(9R)  on  the  left and 
B 10.A(3R) and B 10.HTT on the right (1, 2).  However, when Steinmetz and co- 
workers (3) mapped restriction site polymorphisms in I region DNA, B10.A(3R) 
and  B10.A(5R)  DNA  were  identical.  The  interval  between  I-A  and  I-E  was 
confined  to  3.4  kb,  including  at  least  2  kb  of  the  Ea  gene  (3,  4).  Despite 
considerable evidence supporting placement of l-J within  the I  region  (1,  2,  5, 
6), these results suggested I-J had been incorrectly mapped. 
We recently reconciled these conflicting results (7).  I-J expression is controlled 
by two unlinked genes; one (Jt) maps to chromosome 4 near the b and Fv-I  loci 
and a second is located within the I region, possibly I-E.  Strains B10.A(3R) and 
B10.A(5R)  each  provide  the  requisite  H-2Kgene  for  I-J  k expression,  but  the 
former apparently lacks the appropriate  I-J  k locus on chromosome 4 (reference 
7; summarized in Table I). 
This  report  describes  experiments  to  probe  the jt  contribution  to  the  I-J  k 
molecule. Complementation tests suggest that strain B10.HTT, like B 10.A(3R), 
is probably not  congenic  with  C57BL/10  and  differs from  B10.S(9R) outside 
rather than inside H-2 (the murine major histocompatibility complex) ~. Binding 
of I-JLspecific monoclonal  antibodies to cell surface I-J  k determinants  depends 
on  o~-D-mannosyl  residues  associated  with  protein.  The Jt  gene  product  may 
glycosylate an/-region gene product; alternatively theJt gene product may itself 
be an I-J-bearing glycoprotein expressed only in H-2  k strains. 
Materials and Methods 
Animals.  B10.BR and  A/J mice  were produced in  our colony from breeding pairs 
supplied  by  The Jackson  Laboratory,  Bar  Harbor,  ME.  B10.A,  A.TH,  C57BL/10, 
B10.A(5R),  B10.S(9R), and B 10.A(4R) breeding pairs were generously provided by Dr. 
This work was supported by U.S. Public Health Service Grant number CA-34016 awarded by the 
National Cancer Institute, Dept. of Health and Human Services  training grant T 32 GM 07215, and 
a Steenbock  Career Award to C. E. H. C. E. H. is a Scholar of the Leukemia Society  of America. 
Abbreviations used in this paper:  C, guinea pig serum complement; FCS, fetal calf  serum; H-2, 
murine major histocompatibility  complex; MuLV, Murine Leukemia virus. 
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TABLE  I 
Con~edActionofChromosome-4  and-17gen~ ~ Requi~dforthe ExpresswnofIJ k 
De~rminan~ (~ 
Genes 
/-/-2  jt 
I-Jk  Strains 
expression 
k  +  + 
b  +  - 
b  -- 
b/k  +/-  + 
i3/b  -/+  + 
i3/k  -/-  - 
k  +  + 
BI0,BR, B6-H-2  k, CBA/J, C3H/HeJ,  C58/J, 
MA/MyJ, MRL/MpJ  ÷, RF/J, AKR-Fv-1 b 
AKR/J, CE/J 
C57L, C57BL/6, C57BL/10 
AKR-H-2  b 
(C57L x AKR)F~, (C57BL/6 x AKR)F1, 
(C57BL/10 X AKR)F~ 
(B10.A(3R) × C57BL/10)F~ 
(B10.A(3R) × AKR)F~ 
AKXL strains 13, 14, 28, 38 
AKXL strains 6, 8, 21 
F. H. Bach (University of Minnesota, Minneapolis, MN). Dr. J. H. Stimpfling (McLaughlin 
Research Institute, Great Falls,  MT) kindly donated B10.A(3R) breeding pairs. B6-H-2  k 
mice were the gift of Dr. E.  A.  Boyse (Memorial Sloan-Kettering Cancer Center, New 
York,  NY).  Guinea pigs were from Research Animals Resource Center,  University of 
Wisconsin, Madison, WI. 
Media.  All media and supplements were purchased from Grand Island Biological Co., 
Grand Island, NY. Fetal calf serum (FCS) was from Flow Laboratories, Rockville, MD. 
Antibodies.  Anti-Thy-l.2 serum was made according to Reifand Allen (8). Goat anti- 
mouse immunoglobulin was produced in our laboratory (9). Culture supernatant contain- 
ing anti-I-J  k monoclonal antibody WF8.C 12.8 was kindly provided by Dr. C. Waltenbaugh 
(Northwestern University Medical School, Chicago, IL). 
Hybridoma Production.  B10.A(5R)-immune  B10.A(3R)  splenocytes were  fused  with 
P3NS1/1-Ag4-1  (10)  or  Sp2/0-Agl4  (11)  exactly as  described (12).  Fused  cells  were 
dispensed  into  10  96-well  plates giving clonal growth  in  medium  with  hypoxanthine, 
aminopterin,  and  thymidine  (12).  An  enzyme-linked immunosorbent  assay  (12)  or  a 
microcytotoxicity  assay (I 3) identified clones secreting I-Jk-specific antibodies. Assays used 
B10.A(3R)  and  B10.A(5R)  T  cells.  Clones  were  subcloned  by  limiting  dilution  (12). 
Ouchterlony  gel  diffusion  on  agar-coated  microscope  slides  determined  monoclonal 
antibody heavy and light chain isotype (14).  Heavy and light chain-specific rabbit anti- 
mouse immunoglobulin reagents were from Litton Bionetics, Kensington, MD. 
Microcytotoxicity Assay.  A  two-stage,  dye-exclusion microcytotoxicity assay  was  per- 
formed as described (13).  With WF8.C12.8 IgG~ monoclonal antibodies, a  15-min incu- 
bation of cells with rabbit anti-mouse IgG~ (0.5% in medium  199 with 5% FCS;  Litton 
Bionetics, Kensington, MD)  followed by a  wash  step-preceded guinea pig complement 
addition.  Percentage-specific lysis was corrected for background complement lysis (15). 
Complement backgrounds were <15% on untreated T cells, and <30% on neuraminidase- 
treated T  cells. 
T  Cell Separation.  Lymph  node  cells devoid  of plastic-adherent  cells  were  passed 
through a goat anti-mouse immunoglobulin-Sepharose column as described (16). Effluent 
cells were usually 80-90% Thy-1 positive. 
Enzymes.  Alpha-mannosidase (from jack bean), a-galactosidase (from Aspergillus niger), 
~-N-acetylglucosaminidase (from bovine epididymus), and  C~-L-fucosidase (from bovine 
epididymus) were from Sigma Chemical Co., St. Louis, MO. Vibrea cholerae neuraminidase 
was from Calbiochem-Behring, La Jolla, CA; trypsin, chymotrypsin, and/3-galactosidase 
(from Escherichia coli) were from Miilipore Corp., Freehold, NJ. Glycosidases were purified 
by high pressure liquid chromatography on a Varian TSK G3000 SW column to obtain 
fractions with specific glycosidase activity but without contaminating glycosidase or pro- 1606  CHROMOSOME-4  AND -17  GENES  CONTROL  I-J  k GLYCOPROTEIN 
tease activities. Glycosidase activity was measured by incubating I00 #i enzyme with  100 
#1 p-nitrophenylglycoside (Sigma), 1.0 mM in 0.1 M acetate buffer, pH 4.5, for 1 h, 37°C. 
1 ml glycine buffer,  0.133  M,  with  0.06  M  NaCI and 0.083  M  Na~CO3, pH  10.7,  was 
added and absorbance at 400 nm measured.  1 U  of glycosidase will hydrolyze 1 t~mol p- 
nitrophenylglycoside per hour at 37°C, pH 4.5. Specific activities calculated for purified 
glycosidases were: a-mannosidase, 8.37 U/rag; a-galactosidase, 4.15 U/rag;/~-N-acetyiglu- 
cosaminidase,  4.76  U/mg;  a-L-fucosidase,  7.22  U/rag;  /3-galactosidase,  11.67  U/mg. 
Protease  activity was  assayed  using  casein,  1%  in  0.05  M  Tris-phosphate  buffer,  as  a 
substrate  and  trypsin  and chymotrypsin as standards.  Enzyme (0.02  ml) was incubated 
with  1.0 ml casein  10 rain,  37°C.  1 ml  10% trichloroacetic acid was added, the mixture 
was filtered, and absorbance of the filtrate at 280 nm measured. 
Enzyme Digestion of T Cells.  Purified  T  cells (4  ×  106/ml)  were incubated in  Hank's 
balanced salt solution with 0.1%  sodium azide at pH 6.5 (neuraminidase;  0.02  IU/ml), 
7.0 (other glycosidases), or 7.4 (trypsin) containing 0.005-0.1  IU glycosidase/ml or 0.1 
mg trypsin/ml for 30 min,  37°C in 7.5% CO2. Adding excess cold Hank's balanced salt 
solution with 10% FCS terminated the digestion. Hypotonic lysis removed nonviable cells. 
Cell recoveries ranged from 19-65%; cells were 76-96% viable by trypan blue exclusion. 
Cell Culture.  Culturing trypsin-treated T cells at I ×  106/ml in Mishell-Dutton medium 
(17)  supplemented  with  1  ×  10  -5  M  2-mercaptoethanol  and  5%  FCS for 30-60  rain, 
37°C, 7.5% CO2, removed sodium azide. Growth at 5 ×  106/ml in the same medium for 
18 h, 37°C, 7.5% CO~ allowed protein resynthesis. To some cultures cycloheximide (15 
t~g/ml; Sigma Chemical Co., St.  Louis, MO), tunicamycin (4 #g/ml; Sigma) or monensin 
(1.0 uM; Calbiochem-Behring) were added. After 18 h cells were harvested and nonviable 
cells removed by hypotonic lysis. 
Results 
Neuraminidase Digestion  Alters T  Cells I-j  k Expression.  To detect T  cell surface 
I-J  k  determinants,  I-Jk-specific  monoclonal  antibody  WF8.C12.8  (5)  and  five 
others  produced  in  our  laboratory  (Jk.4,  Jk.5,  Jk.ll,  Jk,14,  and Jk.18)  were 
tested  on  peripheral  T  cells  from  several  recombinant  inbred  strains.  The 
monoclonal antibodies iysed B 10.A, B 10.A(5R), and B10.S(9R), but not C57BL/ 
10, B10.A(3R),  B10.HTT,  or A.TH  T  cells (Table  II and reference  7), charac- 
TABLE  II 
Neuraminidase Digestion Enhances T Cell I-J  ~  Determinant Expression without Altering the 
Strain Distribution Pattern 
T cell  Thy-l.2 antibody  % Cells lysed:*  Jk.18 
donor  WF8.C 12.8 
strain  Untreated  NA*  Untreated  NA  Untreated  NA 
B6-H-2  I'  87 +  1  84 4- 6  13 + 3  42 ± 6  12 4- 2  42 4- 1 
C57B1/10  84 4- 5  87 4- 6  0 4- 0  0 4- 0  0 4- 0  0 4- 0 
B10.A(3R)  82 4- 3  88 ± 2  0 4- 1  1 4- 1  0 4- 0  0 + 0 
BI0.A(4R)  82 + 2  84 4- 0  0 4- 0  2 4- 2  1 4- 1  2 ± 2 
B10.A(SR)  81 4- 1  87 4- 3  13 4- 2  49 4- 10  10 4- 1  46 4- 9 
B10.HTT  80 4- 1  85 4- 5  0 _ 0  0 4- 0  0 4- 0  1 -i- 0 
BI0.S(9R)  854-4  984-2  164-2  514-9  144-2  51±11 
A.TH  83+__6  874-4  1_1  04-0  14-1  2±1 
A/J  844-4  82-1-1  134-1  32±1  144-2  32 :t: 3 
AKR/J  ND  0  ND  1 4- 1  1  4-  1  0  4- 0  1 ±  1 
* Mean 4- SEM; two to four experiments. 
* Neuraminidase  treated. 
~ND, not determined. KLYCZEK  ET  AL.  1607 
teristic of the I-J  k strain distribution (18). B 10.A(5R)-immune B 10.A(3R) splen- 
ocytes, fused with P3NSI/1-Ag4-1  myeloma cells, produced clones Jk.4, Jk.11, 
and Jk.18;  an  Sp2/0-Agl4  myeloma cell fusion yielded clones Jk.5 and Jk.14. 
Jk.11  and Jk.18  are IgM antibodies with kappa light chains. None of the I-J  k- 
specific antibodies lysed B cells (not shown). 
One difficulty in detecting T  cell surface I-J molecules by antibody-mediated 
cytotoxicity is the low I-J determinant frequency in normal T  cell populations 
(18).  Kanno et al. (6) and others (19) routinely treat cells with neuraminidase 
before I-J detection by cytotoxicity (6), fluorescence-activated cell sorter analysis 
(6, 19), and enzyme immuno-electron microscopy (19). We found that neuramin- 
idase specifically increased T  cell I-J  k expression without altering the normal I- 
jk strain distribution pattern (Table II). WF8.C 12.8 and Jk. 18 lysis of B 10.A(5R) 
and  B10.S(9R)  T  cells  increased  three-  to  fourfold,  while  B10.A(3R)  and 
B 10.HTT T  cells remained unreactive. Jk.4, Jk.5, Jk. 11, and Jk. 14 gave similar 
results (not shown). B10.A(3R) anti-B10.A(5R)  I-Jk-specific serum lysed up to 
90% of neuraminidase-treated B 10.S(9R) peripheral T  cells (not shown). AKR/ 
J  (Table  II)  and  CE/J  (not  shown)  T  cells  remained  I-J  k negative  (7)  after 
neuraminidase treatment. 
I-J k Expression  on FI  Hybrid  T  Cells.  We previously reported  (7)  that a  non- 
expressor Jr-  allele  possibly  accounts  for  B10.A(3R)'s  failure  to  express  I-J  k 
structures. Like B 10.A(3 R), B 10.HTT does not express I-J  k structures, although 
it has k haplotype genes in I-E.  We made F~ hybrids between strains B10.HTT 
and  AKR  or  C57BL/10  (Table  III).  Without  neuraminidase  treatment,  I-J  k 
expression by F1 hybrid T  cells was equivocal (not shown). After neuraminidase 
digestion,  antibodies  to  I-J  k lysed (C57BL/10  X  AKR/J)F1  and (B10.HTT  x 
C57BL/10)F~  T  Cells (Table  III).  Without prior neuraminidase digestion,  I-J  k 
molecules on  (3R  x  C57BL/10)Fb  (C57BL/10  x  AKR/J),  and (B10.HTT  X 
C57BL/10)F~  T  cells are probably too  sparse  to detect in our cytotoxic assay 
system.  That  (C57BL/10  x  AKR)F1  hybrid T  cells express  I-J  k determinants 
indicates successful gene complementation between two heterozygous loci. The 
somewhat surprising result that B 10.HTT complements with C57BL/10 but not 
TABLE  II1 
Two Complementing Genes Control I-J k Expression in F1 Hybrid T Cells 
T  cells* donor strain 
Genes  % Cells lysed* 
I-E  Jt  Anti-Thy-  WF8.C12.8  Jk. 18 
1.2 
(C57BL/10 x  AKR)Ft  b/k  +/-  88 ±  2  17 +  3  25 +  4 
(B10.HTT x  AKR)FL  k/k  -/-  91  _+  1  5 _+ 2  2 -  6 
(B10.HTT x  C57BL/10)F1  k/b  -/+  92 ±  3  17 +  6  19 ±  6 
(SR x  AKR-H-2b)FI  k/b  +/-  90 __. 2  27 _+ 2  31  _  7 
(AKR x  B6-H-2k)F1  k/k  -/+  91  _+  1  21  _+ 6  22 +  0 
(B6 x  B6-H-2k)F1  b/k  +/+  85 ±  2  48 +  6  50 +  2 
(B10.A(4R) x  AKR)F~  b/k  +/-  84 ±  3  18 _+ 2  19 ±  5 
(BI0.A(4R) x  B10.A(3R))FI  b/k  +/-  87 ±  4  20 ±. 11  22 +  6 
* Mean _+ SEM; two to five experiments. 
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with AKR/J to yield I-J  k expression suggests that B 10.HTT provides the requisite 
14-2 k gene, but may lack the Jr + allele. B10.HTT must be equivalent to B10.S(9R) 
in H-2, but dissimilar elsewhere. 
FI T  cell I-J k expression is lower than I-J k expression by B10.A(5R) or C57BL/ 
6-H-2 k (Table  II).  We tested possible explanations for this observation (Table 
III). The hybrid (5R x  AKR-H-2b)F1 is heterozygous at both genes, but a single 
parent (B10.A(5R)) donated both positive alleles; I-J k expression on (5R ×  AKR- 
H-2b)F1  T  ceils was not significantly greater than on (C57BL/10  X AKR)F1  T 
cells, where each of the two positive alleles came from a  different parent.  The 
hybrid  (AKR  ×  B6-H-2k)Fx  is  homozygous H-2  k  but  heterozygous Jt +/-.  I-J k 
expression on these T  cells was also diminished, compared with B10.A(5R) or 
C57BL/6-H-2 k. In contrast, (B6 X B6-H-2k)Ft  mice, which are homozygousJt  + 
but  heterozygous  H-2  b/k,  exhibited  T  cell  I-J k  expression  comparable  to 
B10.A(5R)  and  B6-H-2 k.  Thus,  heterozygosity at Jt  but  not H-2  appeared  to 
decrease I-J  k expression. 
Mapping the 14-2 k 1-J-Controlling Gene.  We investigated the H-2 k gene contrib- 
uting to I-J  k expression using recombinant strain B 10.A(4R). B10.A(4R) T  cells 
were  IoJ  k negative  even  after  neuraminidase  treatment  (Table  II).  Crossing 
B10.A(4R) with B10.A(3R) and AKR (7) yielded I-J k positive F1 T  cells (Table 
III); B10.A(4R) thus has a functional Jt  ÷ gene but lacks the H-2 k gene required 
for I-J k expression. B 10.A(4R) is Aa  k, A~  k, Ea  k, E~b; the AaA,~ polypeptide complex 
is expressed on the cell surface in B10.A(4R) mice, whereas the EaE~ complex is 
not. These results rule out the possibility that A~ and Aa genes contribute to the 
I-J k determinant. 
Inhibiting  Protein  Synthesis  or  Glycosylation  Affects  T  Cell  I-J k  Reexpression. 
Enhanced  I-J k expression after  neuraminidase  treatment  (Table  II)  suggested 
that carbohydrate  structures  might be involved in the I-J  k molecule. Previous 
studies (16) demonstrated that the I-J k determinant was associated with protein. 
We therefore attempted to block I-J  k reexpression by preventing protein synthesis 
or glycosylation.  Trypsin  treatment  removed T  cell  surface  I-J  k determinants 
(16). Digested cells were cultured 18 h to allow cell protein resynthesis. Trypsin- 
treated T  cells reexpressed I-J  k determinants after 18 h in culture (Fig. 1). Either 
inhibiting protein synthesis with cycloheximide (20), or blocking protein glyco- 
sylation with tunicamycin (21) or monensin (22) prevented I-J k reexpression (Fig. 
1). Four other I-jk-specific monoclonal antibodies with different clonal origins, 
Jk.4, Jk.5, Jk.11,  and Jk.14,  yielded similar results  (not shown).  Tunicamycin 
allowed cell  surface  expression  of the  unglycosylated protein  moiety of HLA 
(23) and Ia (24) proteins. Similarly,  unglycosylated membrane-bound IgM was 
detected  in  the  presence  of monensin  (22).  However,  blocking glycosylation 
prevents cell surface expression of other membrane glycoproteins such as Thy- 
1 antigen (25).  Apparently, a  glycoprotein carried the I-J  k determinant.  Either 
the I-J k epitope involves carbohydrate chains or unglycosylated I-J protein does 
not reach the cell surface. 
Glycosidase  Treatment  Affects  I-J k Expression.  To  determine  whether  the  I-J k 
epitope involves carbohydrate residues, we measured binding of I-J k antibodies 
to  T  cells  before  and  after  glycosidase  digestion.  T  cells  were  treated  with 
neuraminidase and then with varying concentrations of different purified gly- KLYCZEK ET  AL. 
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trypsin  protein  addition 
treatment  resynthesis  to  culture 
+  +  none 
+  +  cyclohex imide  F 
+  +  tunicomycin  l 
+  +  monensin 
J  I  I 
0  I0  20  30 
%  cells  lysed 
FIGURE 1.  Blocking  protein synthesis  or glycoslyation  prevents T cell I-J  k reexpression  after 
its proteolytic removal. B10.A T cells were treated twice with 0.1 mg trypsin/ml for 30 min, 
37°C. Trypsin-treated T cells were cultured for 18 h with or without cycloheximide  (15/~g/ 
m]), tunicamycin (4  gg/m]), or  monensin (1.0 gM), I-J  k expression was  measured by a 
microcytotoxicity assay with Jk.18  (I) and WF8.C12.8 (W). Mean _+  SEM; two to  three 
experiments. 
cosidases. Alpha-mannosidase completely abrogated I-J  k antibody-dependent lysis 
of neuraminidase-treated  T  cells  in  a  concentration-dependent  manner;  heat- 
inactivated o~-mannosidase had no effect (Fig. 2).  Alpha-galactosidase,/3-galacto- 
sidase, O~-L-fucosidase,  and/3-N-acetylglucosaminidase also had no effect, either 
at concentrations comparable to effective a-mannosidase concentrations (Table 
IV),  or  at  2-20-fold  higher  concentrations  (not  shown).  Similar  results  were 
obtained with Jk.4, Jk.5, Jk. 11,  and Jk.14  antibodies (not shown).  Adding the 
competitive  a-mannosidase  inhibitor p-nitrophenyl-a-n-mannoside blocked  I-J  k 
determinant  removal  from  neuraminidase-treated  T  ceils  (Fig.  3).  Thus  de- 
creased I-J  k is due to a-mannosidase activity and not to a contaminating enzyme 
activity. Alpha-mannosidase treatment also destroyed the I-J  k epitope on T  cells 
without prior neuraminidase treatment (not shown). Thus ~-l>mannosyl residues 
appear to influence the I-J  k epitope recognized by the monoclonal antibodies; if 
other sugar residues are involved, they are not in terminal positions where they 
would be removed by a single glycosidase (26). 
Discussion 
Considerable debate has recently focused on the placement of the enigmatic 
I-J suppressor  determinant controlling gene (4,  27,  28).  Previous experiments 1610  CHROMOSOME-4  AND  -17  GENES  CONTROL  I-J  k  GLYCOPROTEIN 
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Alpha-mannosidase removes I-J  k from the T  cell surface.  B10.BR T  cells were 
treated  with  0.02  IU  neuraminidase/ml  for  30  min,  37°C  as  in  Materials  and  Methods. 
Neuraminidase-digested T  cells were then treated with increasing concentrations of a-man- 
nosidase  for  30  rain.  I-J  k was  measured  in  a  microcytotoxicity  assay  with Jk.18  (O)  and 
WF8.C12.8  (O).  Mean _  SD; one representative experiment of 3.  Squares indicate T  cells 
treated  with  0.018  IU  heat-inactivated  a-mannosidase/ml  and  tested  with Jk.18  (11) or 
WF8.C ! 2.8 (121). 
TABLE  IV 
Alpha-Mannosidase Removes I-J  ~ Determinants from Neuraminidase-treated T Cells* 
Enzyme treatment  i 
% Cells lysed* 
WF8.C12.8  Jk.18 
None  13 +  3  13 _+ 6 
NA I  44 +  9  35 +  9 
NA +  a-galactosidase  47 +  2  46 +  6 
NA +  13-galactosidase  51 _  5  37 +  10 
NA +  a-L-fucosidase  47 +  11  37 _  16 
NA +  a-mannosidase  2 -  3  0 _  0 
NA +  13-N-acetylglucosaminidase  44 +  4  31 ___ 3 
* B10.BR T  cells, neuraminidase treated as in Materials and Methods. 
* Mean _+ SEM; two to six experiments. 
a Enzyme digestion conditions: 0.035 IU a-galactosidase/ml, 0.035 IU O-galactosidase/ml, 0.035 IU 
a-L-fucosidase/ml, 0.018 IU a-mannosidase/ml, 0.035 IU/3-N-acetylglucosaminidase/ml. 
! Neuraminidase. 
provided  evidence  that the action  of an H-2  k gene  together  with a  non-H-2  gene 
is required  for I-J  k expression  (7). A  non-H-2  autosomal  dominant  locus, termed 
Jt and  linked  to  the  b  coat  color  gene  and  Fv-1  on  chromosome  4,  controls  I-J  k 
expression.  The  failure  of strain  B10.HTT,  like  B10.A(3R)  (7),  to  express  I-J  k 
specificities can be attributed  to its background  genes,  rather  than  to an inappro- KLYCZEK  ET  AL.  1611 
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FIGURE 3.  Addition of p-nitrophenyl-a-n-mannose blocks I-J  k removal by a-mannosidase. 
Neuraminidase-treated B 10,BR T  cells were incubated with 0.018 IU a-mannosidase/ml and 
increasing concentrations ofp-nitrophenyl-~-n-mannoside for 30 rain, 37 °C. I-J  k was measured 
by cytotoxicity with Jk. 18 (@) or WF8.C 12.8 (O). Horizontal lines indicate anti-I-J  k lysis after 
neuraminidase treatment alone with Jk.18 (  ) or WF8.C12.8  (- -  -).  Mean +  SEM; two 
experiments. 
priate H-2 k  gene.  Hybrid (B10.HTT  X  C57BL/10)F~  expressed  |_jk  determi- 
nants,  whereas (B10.HTT  X AKR)FI  did not.  In the I-Jk-expressing hybrids, 
B10.HTT  contributed  the  needed  H-2  k  gene  (lacking  in  C57BL/10),  while 
C57BL/10  provided the necessary non-H-2  gene.  In  the non-I-Jk-expressing 
hybrid,  neither  B10.HTT  nor  AKR  could contribute  the  requisite  non-H-2 
gene.  We  therefore  suggest  that  B10.HTT  is  not  fully  H-2-congenic  with 
C57BL/10;  it  lacks a  locus or loci (present in  C57BL/10)  which permits  I-J  k 
expression by B 10.A(5R) and B 10.S(9R). Moreover, the B 10.A(3R) -  B 10.A(5R) 
(7) and B10.HTT -  B10.S(9R) pairs are apparently identical at the H-2  k locus 
required for I-J  k expression. 
The  original  recombinant  (H-2  ~l)  in  B10.HTT's  ancestry  occurred among 
progeny  of a  C3H  x  DBA-T  cross  (29).  This  animal,  crossed  with  A.SW, 
produced a  second recombinant (H-2")  (30).  The second recombinant, crossed 
with B10.S, produced a third recombinant, HTT (30). HTT was backcrossed an 
unknown number of times to C57BL/10 producing the B10.HTT line (29). One 
of these parent strains (most likely A.SW) evidently lacks the Jt  + gene required 
for I-J  k expression, and donated its Jt- genotype to B10.HTT. 
Genes in the I-E subregion probably contribute to the I-J k molecule. Hood et 
al.  (4)  located only four structural genes, A¢, A~, E¢, E~, and one pseudogene, 
EB2 ,  in the I region. The I-J k positive strains B10.A(5R) and B10.S(9R) are k at 
E~, but b and s, respectively, at the other three loci. B10.A(3R) and B10.HTT, 
which have the appropriate H-2 k gene, are both k at E~ but not at the other loci. 
B10.A(4R) is A~  k, A,  k, Ea  k but E,  b and is I-J k negative although it has a functional 
Jt  + gene (Table III). The B10.A(4R) results alone do not rule out E0  k as the I- 
Jk-associated H-2 k gene, since the E~ chain is not expressed on the cell surface 1612  CHROMOSOME-4  AND -17  GENES CONTROL I-J  k GLYCOPROTEIN 
without  intact E~ chain (lacking in  B10.A(4R);  references 31,  32).  Taken  to- 
gether,  however,  these  results  imply  that  the  E,  k gene  is  required  for  I-J k 
expression. Alternatively, in differentiated T  lymphocytes the Ea2 pseudogene 
product may contribute to I-J k molecules. 
Our data suggest that the integrity of the I-J  k epitope recognized by monoclonal 
antibodies depends on terminal a-D-mannosyl residues associated with protein. 
T  cells do not reexpress I-J  k structures when protein synthesis or glycosylation is 
blocked. Alpha-mannosidase cleaves terminal mannosyl residues (26); this enzyme 
destroyed I-J  k epitopes.  Wieder et  al.  (33)  drew  a  different conclusion;  they 
found I-J  k determinants on  in  vitro  translated proteins presumably devoid of 
carbohydrate. Terminal mannosyl residues occur on simple,  or high-mannose 
types of oligosaccharides (34).  Neuraminidase treatment increased T  cell  I-J  k 
expression; this probably does not imply that sialic acid residues are attached to 
the nonreducing ends of some high-mannose, I-Jk-bearing carbohydrate chains. 
Only complex type carbohydrate chains have to date borne terminal sialic acid 
residues (34).  Furthermore, it seems unlikely that mannosyl groups themselves 
form the I-J  k epitope, since these residues are so prevalent on mammalian cells. 
Mannosyl residues might instead be important in maintaining the structure of 
the I-J  k protein or carbohydrate chains. 
Mannosyl residues may be implicit in functional suppressor T  cell interactions. 
Interestingly, the T  cell mitogenic lectin concanavalin A, whose ligand is a-D- 
mannose, bound specifically to I-J positive T  cells initiating T  cell proliferation 
(35) and increased nonspecific suppressor cell activity (36). Moreover, methyl-a- 
D-mannoside inhibited suppressor T cell induction in an aliogeneic response (37). 
Finally, a-D-mannose reversed infectious mononucleosis-associated suppressor T 
cell activity in vitro (38). 
A  number of models may account for expression of the I-J k molecule. It is 
unlikely that the I-J  k epitope is formed by association of two polypeptide chains, 
since I-J specificities occur on single polypeptide chains (39, 40). Likewise, DNA 
rearrangements occurring in T  lymphocytes to juxtapose the H-2 and Jt genes 
such that a single transcript might encode a polypeptide with two domains are 
unlikely because the two genes are unlinked. Finally, intra-I-region rearrange- 
ments have not been found in T  cells (27). 
We consider two models most likely. First,  one gene product might modify 
(cleave, glycosylate, phosphorylate, or acylate) the other structural gene product 
(4).  Since B cells synthesize 1-region polypeptides but do not express I-J deter- 
minants (4,  15,  17,  18),  the Jt gene product might be enzymatically active only 
in differentiated T  lymphocytes. I-J k molecules might be formed from E~ or E~ 
polypeptides processed  differently in Jt-expressing  T  cells  than  in  B  cells  or 
macrophages. Ikezawa et al. (41) concluded that I-J  k determinants resulted from 
Ee  k chain modification. However, the Y17 monoclonal antibody used in experi- 
ments from which these conclusions were drawn does not bind E~ or Ea chains 
alone (42), but recognizes a combinatorial E~Eo determinant (42). Furthermore, 
if the  I-Jk-bearing structure were a  receptor binding  to  E~ or  E¢ chains (see 
below) both I-E and I-J determinants could be closely associated, as these studies 
indicate, but not part of the same polypeptide; conditions that would dissociate 
noncovalently bound polypeptides were not used. T  suppressor cell lines did not KLYCZEK ET  AL.  1613 
yield /-region  hybridizing  mRNA  (28).  However,  I-J k expression  is  cell  cycle 
dependent (19); nonsynchronous cells were used and I-J  k molecule synthesis was 
not  demonstrated  at  the  time  of  mRNA  extraction  (28).  Finally,  E~  or  E~ 
polypeptide molecular weights do not match reported I-J k polypeptide weights 
(40, 43-46). 
A second hypothesis postulates that I-J synthesis is regulated by a second gene. 
Thus,Jt may be a structural gene, its transcription and/or translation controlled 
by E~ or Ea gene expression on other cells.  For example, the T  cell receptor 
molecule specific for self E,Ea complexes on antigen-presenting cells or B cells 
might bear I-J k epitopes. The receptor may be induced only when appropriate 
H-2 molecule(s) (e.g. I-E) are expressed during maturation.  Genetic control of 
the receptor, and therefore of I-J  k specificities, would then apparently map to 
the H-2 gene. Some evidence supports this model. I-J-bearing,  antigen-specific 
suppressor T  cells are restricted by, and probably bind, I-E;  Baxevanis and co- 
workers  (47-49)  demonstrated  that  monoclonal  anti-I-E  antibodies  blocked 
antigen-specific  suppressor  T  cell  induction.  Furthermore,  antibodies  to  I-J k 
blocked binding of primed T  cells to antigen-pulsed macrophages (K. Klyczek, 
preliminary results). I-J alleles might represent different receptor molecules co- 
selected with the I-E gene product or selected by adaptive modification of the Jt 
gene product. 
Genetic  control  of the  Murine  Leukemia virus  (MuLV)  antigen  Gix  shows 
striking similarities to that of I-J k. Glx and I-J ~ are not expressed in all mouse 
strains or tissues. Both show hemizygous expression in heterozygotes and Men- 
delian segregation  of loci (50).  Gix  is expressed as a  thymocyte carbohydrate 
differentiation antigen carried on the viral glycoprotein gp70 (51, 52). The same 
genes that govern Gix viral antigen expression could potentially also affect I-J 
expression. Gv-I governs Gix cell surface density (53). The exact location of Gv- 
1 is unclear. Segregation data suggested genetic linkage of Gv-1  to both Gpd-1 
(chromosome 4) and H-2 (chromosome 17) (54).  Stockert et al. (54) attributed 
this "quasi-linkage" to the fact that both Fv-1  (very near Gpd-1) (55) and an/4- 
2D-linked gene (56) appear to influence MuLV replication, and thus simulate 
genetic linkage. The apparent chromosomal location of the I-J-controlling genes 
on chromosomes 4  and  17  might reflect a  similar mechanism. The possibility 
that I-J genes may be derived from or associated with genes influencing virus 
expression is intriguing.  Others have speculated that integrated viral genomes 
are  not simply intruders,  but are  themselves elements of the cellular genome 
with vital physiological functions (57). 
Summary 
Two genes acting in concert control murine T  cell I-J  k expession. We deter- 
mined I-J k expression with I-Jk-specific monoclonal antibodies WF8.C12.8  and 
five others produced in our laboratory in a  cytotoxicity assay.  Previous experi- 
ments established that an/-/-2 ~ gene and a chromosome 4 gene, Jt, regulate I-J  k 
expression (7). We show here that B10.HTT and B10.S(9R) do not differ at the 
14-2  k locus required for I-J  k expression. Rather B10.HTT, like BI0.A(3R), lacks 
some important non-H-2 gene (possibly Jr). The intra-H-2 k I-J-controlling locus 
maps to the right of the I-A subregion. The I-J  k determinant involves a  carbo- 1614  CHROMOSOME-4  AND  -17  GENES CONTROL  I-J  k GLYCOPROTEIN 
hydrate structure associated with protein; inhibiting either protein synthesis or 
gtycosylation prevents T  cell I-J  k reexpression after proteotytic removal. Treat- 
ment with a-naannosidase  destroys I-J  k determinants,  implicating terminal  a-D- 
mannosyl  residues  in  the  I-J  k  epitope.  Models  for H-2  and Jt  control  of I-J 
expression are discussed. 
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